Browsing Tag
EGFR
6 posts
Johnson & Johnson strengthens oncology delivery strategy with EU nod for subcutaneous amivantamab
EU approves subcutaneous amivantamab for EGFR lung cancer. Discover how this could reshape oncology workflows and Johnson & Johnson’s strategy.
Can dual-targeting therapies redefine second-line colorectal cancer treatment in 2026?
Can dual-targeting therapies like amivantamab transform second-line colorectal cancer care? Explore what’s changing and who stands to win. Read the full story.
Black Diamond Therapeutics reports strong early Phase 2 response for silevertinib in first-line NSCLC patients
Discover how Black Diamond Therapeutics’ silevertinib achieved a 60% response in first-line lung cancer and why its upcoming glioblastoma trial could reshape targeted oncology.
Merus N.V. stock soars on breakthrough cancer trial: What drove MRUS to the top gainers list?
Merus N.V. stock jumped 32% on breakthrough cancer trial data. Find out what’s driving MRUS and what could come next for this biotech leader.
Janssen’s subcutaneous amivantamab gains CHMP backing for EGFR-mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a…
Pfizer’s Vizimpro receives EMA approval recommendation for NSCLC treatment
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost…